Performance Evaluation of G8, a High-Sensitivity Benchtop Preclinical PET/CT Tomograph

Gu, Zhichen; Taschereau, Richard; Vu, Nam T.; Prout, David; Silverman, Robert W.; Lee, Jason T.; Chatziioannou, Arion F.

doi:10.2967/jnumed.118.208827

Cited by 27 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a separate experiment, PET/CT scans were performed using a small-animal bench-top PET/CT scanner 40 (G8, Perkin Elmer, Massachusetts, U.S), as previously reported, with a set energy window ranging from 150 keV to 650 keV 41 . Mice were subcutaneously inoculated with PC-3 PIP tumor cells (6 × 10 6 cells) and PC-3 flu tumors cells (5 × 10 6 cells) on the right and left shoulder, respectively, 7–10 days before the acquisition of the PET/CT scans.…”

Section: Methodsmentioning

confidence: 99%

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

Umbricht

Köster

Bernhardt

et al. 2019

Sci Rep

View full text Add to dashboard Cite

In this study, it was aimed to investigate 149Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. 149Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. 149Tb-PSMA-617 was applied at 1 × 6 MBq (Day 0) or 2 × 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 × 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the β+-emission of 149Tb, tumor localization was feasible using PET/CT after injection of 149Tb-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of 149Tb-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of 149Tb for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand’s tissue distribution.

show abstract

Section: Methodsmentioning

confidence: 99%

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

Umbricht

Köster

Bernhardt

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…PET/CT scans were performed using a small-animal bench-top PET/CT scanner (G8, Perkin Elmer, Waltham, MA, USA.) in order to qualitatively estimate the delivered dose distribution by PT [24]). Due to the compact size of this scanner, it was possible to transport it from CRS to CPT to the OPTIS2 treatment room.…”

Section: Methodsmentioning

confidence: 99%

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute

et al. 2019

View full text Add to dashboard Cite

Proton therapy (PT) is a treatment with high dose conformality that delivers a highly-focused radiation dose to solid tumors. Targeted radionuclide therapy (TRT), on the other hand, is a systemic radiation therapy, which makes use of intravenously-applied radioconjugates. In this project, it was aimed to perform an initial dose-searching study for the combination of these treatment modalities in a preclinical setting. Therapy studies were performed with xenograft mouse models of folate receptor (FR)-positive KB and prostate-specific membrane antigen (PSMA)-positive PC-3 PIP tumors, respectively. PT and TRT using 177Lu-folate and 177Lu-PSMA-617, respectively, were applied either as single treatments or in combination. Monitoring of the mice over nine weeks revealed a similar tumor growth delay after PT and TRT, respectively, when equal tumor doses were delivered either by protons or by β¯-particles, respectively. Combining the methodologies to provide half-dose by either therapy approach resulted in equal (PC-3 PIP tumor model) or even slightly better therapy outcomes (KB tumor model). In separate experiments, preclinical positron emission tomography (PET) was performed to investigate tissue activation after proton irradiation of the tumor. The high-precision radiation delivery of PT was confirmed by the resulting PET images that accurately visualized the irradiated tumor tissue. In this study, the combination of PT and TRT resulted in an additive effect or a trend of synergistic effects, depending on the type of tumor xenograft. This study laid the foundation for future research regarding therapy options in the situation of metastasized solid tumors, where surgery or PT alone are not a solution but may profit from combination with systemic radiation therapy.

show abstract

“…The preclinical G8 PET/CT system (Sofie BioSciences, Perkin-Elmer) (24), the successor of the preclinical PET/CT system Genisys 4 (Sofie BioSciences) (25), was used in this study. The G8 applies a dead-time correction to the data; however, it is accurate only up to a photon flux produced by a mouse injected with 3 MBq of 18 F-FDG.…”

Section: Pet Imaging and Image Evaluationmentioning

confidence: 99%

Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux

et al. 2018

View full text Add to dashboard Cite

Performing PET imaging during ongoing radionuclide therapy can be a promising method to follow tumor response in vivo. However, the high therapeutic activity can interfere with the PET camera performance and degrade both image quality and quantitative capabilities. As a solution, low-energy photon emissions from the therapeutic radionuclide can be highly attenuated, still allowing sufficient detection of annihilation photons in coincidence. Methods: Hollow Rose metal cylinders with walls 2-4 mm thick were used to shield a 22 Na point source and a uniform phantom filled with 18 F as they were imaged on a preclinical PET camera with increasing activities of 177 Lu. A mouse with a subcutaneous tumor was injected with 18 F-FDG and imaged with an additional 120 MBq of 177 Lu and repeated with shields surrounding the animal. Results: The addition of 177 Lu to the volume imaged continuously degraded the image quality with increasing activity. The image quality was improved when shielding was introduced. The shields showed a high ability to produce stable and reproducible results for both spatial resolution and quantification of up to 120 MBq of 177 Lu activity (maximum activity tested). Conclusion: Without shielding, the activity quantification will be inaccurate for time points at which therapeutic activities are high. The suggested method shows that the shields reduce the noise induced by the 177 Lu and therefore enable longitudinal quantitative intratherapeutic imaging studies.To improve cancer therapy, there is a need for sensitive and quantitative molecular imaging techniques to follow therapeutic efficacy and progress of disease (1,2).In preclinical research, molecular imaging techniques such as PET help decipher the response to treatment in animal tumor models. Changes in proliferation, hypoxia, angiogenesis, and other factors important to tumor growth and survival can be monitored in vivo with PET tracers (2-5). PET adds physiologic information that can have better prognostic value than measuring tumor size and volume with calipers or with morphologic imaging such as CT or MRI (6). PET tracers enable longitudinal studies, allowing measurements of both early and late treatment response (7).Radionuclide therapy (RNT) is an expanding field of systemic therapies in which tumor-targeting molecules are labeled with radionuclides to deliver localized radiotherapy to tumor cells with high specificity. 177 Lu-DOTATATE is a recent effective RNT for the treatment of neuroendocrine tumors, and several other promising treatments are currently under development (8,9), such as 177 Lu-prostate-specific membrane antigen treatment for metastatic prostate cancer (10-12). Radionuclides used for RNT are chosen for their mode of decay and the linear energy transfer of the emitted particles. To follow response markers in vivo with PET can be both a step toward more personalized medicine and a tool to broaden the radiobiologic understanding of RNT.However, photon emissions from RNT radionuclides can interfere during intratherapeutic P...

show abstract

Performance Evaluation of G8, a High-Sensitivity Benchtop Preclinical PET/CT Tomograph

Cited by 27 publications

References 25 publications

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute

Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux

Contact Info

Product

Resources

About